RARE Fell 26% In A Week. Not Its Worst Week Ever
- RARE has experienced significant declines in the past, dropping nearly 60% during the 2018 Correction and the Covid Pandemic, and around 58% during the Inflation Shock, each time surpassing the S&P 500’s declines in these instances.
- Recovery takes time. RARE took about 11 months to recover from the 2018 Correction and the COVID pandemic, whereas it has not yet fully recovered from the Inflation Shock.
Ultragenyx Pharmaceutical Stock Performance In Market Crashes:
| RARE | S&P 500 | |
|---|---|---|
| 2018 Correction | ||
| % Change from Pre-Recession Peak | -60% | -20% |
| # of Months for Full Recovery | 11 | 4 |
| Covid Pandemic | ||
| % Change from Pre-Recession Peak | -60% | -34% |
| # of Months for Full Recovery | 11 | 5 |
| Inflation Shock | ||
| % Change from Pre-Recession Peak | -58% | -25% |
| # of Months for Full Recovery | Yet to Recover | 15 |
Worried that RARE is yet to hit the bottom? You could take a look at the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Relevant Articles